GlassScriptPhysician profile
Lori Catherine Bubb
NPI 1124006424
$1,075.43
in general payments reported to CMS, 2019-2025
23 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $31.84 · 2021: $25.32 · 2022: $104 · 2023: $90.03 · 2024: $334 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $192.07 | 2019-2025 | Nexium, Breztri, Airsupra |
| Lilly USA, LLC | $129.65 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $109.84 | 2019-2024 | Ubrelvy |
| Abbott Laboratories | $96.51 | 2019-2024 | Octrode, Proclaim |
| Pfizer INC. | $91.60 | 2019-2025 | |
| Novo Nordisk INC | $84.18 | 2019-2025 | Wegovy, Rybelsus |
| Amgen INC. | $41.90 | 2025 | Evenity, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $39.66 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.99 | 2019-2024 | Xifaxan |
| Seqirus USA INC | $34.35 | 2022-2024 | Fluad, Flucelvax |
| Bayer Healthcare Pharmaceuticals INC. | $29.94 | 2022-2024 | |
| Neos Therapeutics, LP | $20.02 | 2019 | |
| Astellas Pharma US INC | $18.70 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $18.42 | 2019 | |
| Merck Sharp & Dohme LLC | $16.96 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.82 | 2020 | |
| Corcept Therapeutics | $16.64 | 2024 | Korlym |
| Dexcom, INC. | $16.58 | 2019 | |
| Kaleo, INC. | $14.32 | 2019 | |
| Cranial Technologies, INC | $13.36 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.16 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.42 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Bubb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.